Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Rivanna Medical, Inc.
- Study ID
- NCT07853768
- Status
- Recruiting
Conditions
- Ankle Injury
- Fracture Arm
- Fracture Leg
- Wrist Injury
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Accuro XV Ultrasound Imaging System — DEVICEThe Accuro XV Ultrasound Imaging System is a cart-based ultrasound imaging device designed to acquire volumetric images of bone and soft tissue anatomy of the distal extremities. In this study, participants will undergo additional Accuro XV imaging following standard-of-care imaging for a distal extremity injury. The imaging procedure includes acquisition of multiple views of the injured anatomy using ultrasound technology and advanced image-processing methods to generate three-dimensional representations of bone and soft tissue structures. Images collected during the study will be used to evaluate device feasibility, safety, image quality, and to support the development and testing of future algorithms. Accuro XV imaging results will not be used for clinical decision-making.
Study Details
The Accuro XV is a cart-based, bedside ultrasound instrument that incorporates new signal processing-based technologies for enhanced bone and soft-tissue imaging. Patients presenting to the Study Setting (e.g., Emergency Departments, urgent care centers, orthopedic clinics, radiology departments, and other clinical environments with access to standard-of-care (SOC) imaging with a suspected distal extremity injury (wrist, forearm, ankle, or lower leg) who have undergone SOC imaging during their clinical evaluation, will be enrolled for additional extremity imaging with the Accuro XV. In this feasibility study, investigators will assess the safety of Accuro XV by review of any adverse events (AEs) and by comparing the comfort level of patients during Accuro XV image capture and standard-of-care imaging. Investigators will retrospectively assess image quality by reviewing all images captured to ensure the image is clear of artifact and other visual imperfections. The de-identified imaging data will then be used for algorithm development and testing. This data will help to verify plans for future study protocols and help to ensure the device is optimized for its clinical use prior to further clinical studies. The results will also be used as an input to RIVANNA's usability and human factors engineering process per IEC 60601-1-6 as recognized by FDA. The Accuro XV is investigational in this study and is not intended to guide clinical decision-making.
Key Dates
- First listed
- Oct 2, 2026
- Start date
- Jan 29, 2024
- Status verified
- Oct 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 25,000 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Accuro XV ImagingParticipants with a distal extremity injury who have undergone standard-of-care imaging will receive additional imaging with the Accuro XV ultrasound imaging system. Accuro XV imaging will be performed after completion of standard-of-care clinical imaging and will not be used for clinical decision-making or patient management. Imaging data collected during the study will be used to evaluate device feasibility, safety, image quality, and to support the development and testing of future algorithms.
Primary Outcome Measure
Accuro XV Image Quality Assessment [ Time Frame: From Accuro XV image acquisition through completion of retrospective image-quality assessment, up to 48 months. ]
Central Contacts
- Delphine Le Roux, PhD804-514-0589
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of California San Francisco | San Francisco | California | 94143 | Aaron Kornblith, MD (PRINCIPAL_INVESTIGATOR) |
| The University of Colorado Denver | Denver | Colorado | 80204 | Matthew Riscinti, MD (PRINCIPAL_INVESTIGATOR) |
| Yale University | New Haven | Connecticut | 06510 | Cristiana Baloescu, MD (PRINCIPAL_INVESTIGATOR) |
| Rush University Medical Center | Chicago | Illinois | 60612 | Michael Gottlieb, MD (PRINCIPAL_INVESTIGATOR) |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | Jason Fields, MD (PRINCIPAL_INVESTIGATOR) |
| The University of Texas Southwestern | Dallas | Texas | 75390 | Philip Jarrett, MD (PRINCIPAL_INVESTIGATOR) |
| Texas Tech University Health Sciences Center | El Paso | Texas | 79905 | Kara Samsel, MD (PRINCIPAL_INVESTIGATOR) |
| The University of Utah | Salt Lake City | Utah | 84112 | Christopher Kelly, MD (PRINCIPAL_INVESTIGATOR) |
| The University of Virginia | Charlottesville | Virginia | 22904 | Christopher Thom, MD (PRINCIPAL_INVESTIGATOR) |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Jordan Tozer (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
Related Studies
- Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture CareRecruiting · LifeNet Health · Orlando, Florida
- Dance Mental Health AppRecruiting · University of California, San Diego · San Diego, California
- A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid RequirementsPHASE4 · Recruiting · Nemours Children's Clinic · Wilmington, Delaware